Abstract
Summary
LPI (LP Information)' newest research report, the “Psychiatric API Industry Forecast” looks at past sales and reviews total world Psychiatric API sales in 2022, providing a comprehensive analysis by region and market sector of projected Psychiatric API sales for 2023 through 2029. With Psychiatric API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psychiatric API industry.
This Insight Report provides a comprehensive analysis of the global Psychiatric API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psychiatric API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Psychiatric API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psychiatric API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psychiatric API.
The global Psychiatric API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Psychiatric API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Psychiatric API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Psychiatric API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Psychiatric API players cover Pfizer, Eli Lilly, Salutas Pharma, Bora Pharmaceutical, Dr.Reddy's Laboratories, Germany Pharmaceutical, Hengrui Pharmaceuticals, Herui Pharmaceutical and Ren An Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Psychiatric API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Venlafaxine
Duloxetine
Olanzapine
Paroxetine
Others
Segmentation by application
Major Depressive Disorder
Generalized Anxiety Disorder
Fibromyalgia
Schizophrenia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Eli Lilly
Salutas Pharma
Bora Pharmaceutical
Dr.Reddy's Laboratories
Germany Pharmaceutical
Hengrui Pharmaceuticals
Herui Pharmaceutical
Ren An Pharmaceutical
Yaopharma
Kanghong Pharmaceutical
Brilliant Pharmaceutical
Dongting Pharmaceutical
Sichuan Chuanda West China Pharmaceutical
Yangtze River Pharmaceutical
Huahai Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Psychiatric API market?
What factors are driving Psychiatric API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psychiatric API market opportunities vary by end market size?
How does Psychiatric API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
This Insight Report provides a comprehensive analysis of the global Psychiatric API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psychiatric API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Psychiatric API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psychiatric API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psychiatric API.
The global Psychiatric API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Psychiatric API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Psychiatric API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Psychiatric API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Psychiatric API players cover Pfizer, Eli Lilly, Salutas Pharma, Bora Pharmaceutical, Dr.Reddy's Laboratories, Germany Pharmaceutical, Hengrui Pharmaceuticals, Herui Pharmaceutical and Ren An Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Psychiatric API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Venlafaxine
Duloxetine
Olanzapine
Paroxetine
Others
Segmentation by application
Major Depressive Disorder
Generalized Anxiety Disorder
Fibromyalgia
Schizophrenia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Eli Lilly
Salutas Pharma
Bora Pharmaceutical
Dr.Reddy's Laboratories
Germany Pharmaceutical
Hengrui Pharmaceuticals
Herui Pharmaceutical
Ren An Pharmaceutical
Yaopharma
Kanghong Pharmaceutical
Brilliant Pharmaceutical
Dongting Pharmaceutical
Sichuan Chuanda West China Pharmaceutical
Yangtze River Pharmaceutical
Huahai Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Psychiatric API market?
What factors are driving Psychiatric API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psychiatric API market opportunities vary by end market size?
How does Psychiatric API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Psychiatric API Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Psychiatric API by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Psychiatric API by Country/Region, 2018, 2022 & 2029
2.2 Psychiatric API Segment by Type
2.2.1 Venlafaxine
2.2.2 Duloxetine
2.2.3 Olanzapine
2.2.4 Paroxetine
2.2.5 Others
2.3 Psychiatric API Sales by Type
2.3.1 Global Psychiatric API Sales Market Share by Type (2018-2023)
2.3.2 Global Psychiatric API Revenue and Market Share by Type (2018-2023)
2.3.3 Global Psychiatric API Sale Price by Type (2018-2023)
2.4 Psychiatric API Segment by Application
2.4.1 Major Depressive Disorder
2.4.2 Generalized Anxiety Disorder
2.4.3 Fibromyalgia
2.4.4 Schizophrenia
2.4.5 Others
2.5 Psychiatric API Sales by Application
2.5.1 Global Psychiatric API Sale Market Share by Application (2018-2023)
2.5.2 Global Psychiatric API Revenue and Market Share by Application (2018-2023)
2.5.3 Global Psychiatric API Sale Price by Application (2018-2023)
3 Global Psychiatric API by Company
3.1 Global Psychiatric API Breakdown Data by Company
3.1.1 Global Psychiatric API Annual Sales by Company (2018-2023)
3.1.2 Global Psychiatric API Sales Market Share by Company (2018-2023)
3.2 Global Psychiatric API Annual Revenue by Company (2018-2023)
3.2.1 Global Psychiatric API Revenue by Company (2018-2023)
3.2.2 Global Psychiatric API Revenue Market Share by Company (2018-2023)
3.3 Global Psychiatric API Sale Price by Company
3.4 Key Manufacturers Psychiatric API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Psychiatric API Product Location Distribution
3.4.2 Players Psychiatric API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Psychiatric API by Geographic Region
4.1 World Historic Psychiatric API Market Size by Geographic Region (2018-2023)
4.1.1 Global Psychiatric API Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Psychiatric API Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Psychiatric API Market Size by Country/Region (2018-2023)
4.2.1 Global Psychiatric API Annual Sales by Country/Region (2018-2023)
4.2.2 Global Psychiatric API Annual Revenue by Country/Region (2018-2023)
4.3 Americas Psychiatric API Sales Growth
4.4 APAC Psychiatric API Sales Growth
4.5 Europe Psychiatric API Sales Growth
4.6 Middle East & Africa Psychiatric API Sales Growth
5 Americas
5.1 Americas Psychiatric API Sales by Country
5.1.1 Americas Psychiatric API Sales by Country (2018-2023)
5.1.2 Americas Psychiatric API Revenue by Country (2018-2023)
5.2 Americas Psychiatric API Sales by Type
5.3 Americas Psychiatric API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Psychiatric API Sales by Region
6.1.1 APAC Psychiatric API Sales by Region (2018-2023)
6.1.2 APAC Psychiatric API Revenue by Region (2018-2023)
6.2 APAC Psychiatric API Sales by Type
6.3 APAC Psychiatric API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Psychiatric API by Country
7.1.1 Europe Psychiatric API Sales by Country (2018-2023)
7.1.2 Europe Psychiatric API Revenue by Country (2018-2023)
7.2 Europe Psychiatric API Sales by Type
7.3 Europe Psychiatric API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Psychiatric API by Country
8.1.1 Middle East & Africa Psychiatric API Sales by Country (2018-2023)
8.1.2 Middle East & Africa Psychiatric API Revenue by Country (2018-2023)
8.2 Middle East & Africa Psychiatric API Sales by Type
8.3 Middle East & Africa Psychiatric API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Psychiatric API
10.3 Manufacturing Process Analysis of Psychiatric API
10.4 Industry Chain Structure of Psychiatric API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Psychiatric API Distributors
11.3 Psychiatric API Customer
12 World Forecast Review for Psychiatric API by Geographic Region
12.1 Global Psychiatric API Market Size Forecast by Region
12.1.1 Global Psychiatric API Forecast by Region (2024-2029)
12.1.2 Global Psychiatric API Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Psychiatric API Forecast by Type
12.7 Global Psychiatric API Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Psychiatric API Product Portfolios and Specifications
13.1.3 Pfizer Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly Psychiatric API Product Portfolios and Specifications
13.2.3 Eli Lilly Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Salutas Pharma
13.3.1 Salutas Pharma Company Information
13.3.2 Salutas Pharma Psychiatric API Product Portfolios and Specifications
13.3.3 Salutas Pharma Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Salutas Pharma Main Business Overview
13.3.5 Salutas Pharma Latest Developments
13.4 Bora Pharmaceutical
13.4.1 Bora Pharmaceutical Company Information
13.4.2 Bora Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.4.3 Bora Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Bora Pharmaceutical Main Business Overview
13.4.5 Bora Pharmaceutical Latest Developments
13.5 Dr.Reddy's Laboratories
13.5.1 Dr.Reddy's Laboratories Company Information
13.5.2 Dr.Reddy's Laboratories Psychiatric API Product Portfolios and Specifications
13.5.3 Dr.Reddy's Laboratories Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Dr.Reddy's Laboratories Main Business Overview
13.5.5 Dr.Reddy's Laboratories Latest Developments
13.6 Germany Pharmaceutical
13.6.1 Germany Pharmaceutical Company Information
13.6.2 Germany Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.6.3 Germany Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Germany Pharmaceutical Main Business Overview
13.6.5 Germany Pharmaceutical Latest Developments
13.7 Hengrui Pharmaceuticals
13.7.1 Hengrui Pharmaceuticals Company Information
13.7.2 Hengrui Pharmaceuticals Psychiatric API Product Portfolios and Specifications
13.7.3 Hengrui Pharmaceuticals Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Hengrui Pharmaceuticals Main Business Overview
13.7.5 Hengrui Pharmaceuticals Latest Developments
13.8 Herui Pharmaceutical
13.8.1 Herui Pharmaceutical Company Information
13.8.2 Herui Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.8.3 Herui Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Herui Pharmaceutical Main Business Overview
13.8.5 Herui Pharmaceutical Latest Developments
13.9 Ren An Pharmaceutical
13.9.1 Ren An Pharmaceutical Company Information
13.9.2 Ren An Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.9.3 Ren An Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Ren An Pharmaceutical Main Business Overview
13.9.5 Ren An Pharmaceutical Latest Developments
13.10 Yaopharma
13.10.1 Yaopharma Company Information
13.10.2 Yaopharma Psychiatric API Product Portfolios and Specifications
13.10.3 Yaopharma Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Yaopharma Main Business Overview
13.10.5 Yaopharma Latest Developments
13.11 Kanghong Pharmaceutical
13.11.1 Kanghong Pharmaceutical Company Information
13.11.2 Kanghong Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.11.3 Kanghong Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Kanghong Pharmaceutical Main Business Overview
13.11.5 Kanghong Pharmaceutical Latest Developments
13.12 Brilliant Pharmaceutical
13.12.1 Brilliant Pharmaceutical Company Information
13.12.2 Brilliant Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.12.3 Brilliant Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Brilliant Pharmaceutical Main Business Overview
13.12.5 Brilliant Pharmaceutical Latest Developments
13.13 Dongting Pharmaceutical
13.13.1 Dongting Pharmaceutical Company Information
13.13.2 Dongting Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.13.3 Dongting Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Dongting Pharmaceutical Main Business Overview
13.13.5 Dongting Pharmaceutical Latest Developments
13.14 Sichuan Chuanda West China Pharmaceutical
13.14.1 Sichuan Chuanda West China Pharmaceutical Company Information
13.14.2 Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.14.3 Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Sichuan Chuanda West China Pharmaceutical Main Business Overview
13.14.5 Sichuan Chuanda West China Pharmaceutical Latest Developments
13.15 Yangtze River Pharmaceutical
13.15.1 Yangtze River Pharmaceutical Company Information
13.15.2 Yangtze River Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.15.3 Yangtze River Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Yangtze River Pharmaceutical Main Business Overview
13.15.5 Yangtze River Pharmaceutical Latest Developments
13.16 Huahai Pharmaceutical
13.16.1 Huahai Pharmaceutical Company Information
13.16.2 Huahai Pharmaceutical Psychiatric API Product Portfolios and Specifications
13.16.3 Huahai Pharmaceutical Psychiatric API Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Huahai Pharmaceutical Main Business Overview
13.16.5 Huahai Pharmaceutical Latest Developments
14 Research Findings and Conclusion